Widespread livedo racemosa

descriptionPublicationkeyboard_double_arrow_right Article 13 Apr 2023 English Publisher:Oxford University Press (OUP)Journal:Clinical and Experimental Dermatology, volume 48, pages 945-948 (issn: 0307-6938, eissn: 1365-2230,

Copyright policy )

Authors: Patricia Zhao; Lydia A Luu; Tappy J Gish; Shyam S Raghavan; Alejandro A Gru; Barrett J Zlotoff;

doi: 10.1093/ced/llad138

pmid: 37052078

Widespread livedo racemosa

- Summary
- Subjects
- Metrics

Abstract

A 41-year-old woman with monoclonal gammopathy of undetermined significance presented with a 1-year history of livedo racemosa that started on one arm after receiving the Pfizer BioNTech COVID-19 vaccine. Her primary care physician initially thought it was a benign reaction to the COVID-19 vaccine as her symptoms were on the same arm as the site of injection. However, the livedo racemosa subsequently became more widespread after COVID-19 infection.

Related Organizations

University of Virginia Medical Center
United States
University of Virginia
United States

Keywords

Humans, Livedo Reticularis

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average